Cargando…

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials

The risk for acquiring human papillomavirus (HPV) infections and associated diseases is lifelong. An important part of prophylactic HPV vaccine development is durable protection against infection and disease. With comprehensive long-term follow-up (LTFU) in adolescents, men, and women, the quadrival...

Descripción completa

Detalles Bibliográficos
Autor principal:	Goldstone, Stephen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	HPV
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038021/ https://www.ncbi.nlm.nih.gov/pubmed/36916016 http://dx.doi.org/10.1080/21645515.2023.2184760

Ejemplares similares

The use of urine in the follow-up of HPV vaccine trials
por: Vorsters, Alex, et al.
Publicado: (2015)

The influence of political ideology on awareness of HPV and HPV vaccine among adults in the United States
por: Chido-Amajuoyi, Onyema Greg, et al.
Publicado: (2023)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge
por: Hoes, J., et al.
Publicado: (2021)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age
por: Zhao, Chao, et al.
Publicado: (2022)

Parents’ stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors
por: McKenzie, Ashley Hedrick, et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation
por: Ishimoto, Tatsuki, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States
por: Meites, Elissa, et al.
Publicado: (2022)

Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination
por: Osaghae, Ikponmwosa, et al.
Publicado: (2022)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China
por: Wu, Huamei, et al.
Publicado: (2023)

Changing trends in HPV vaccination in Japan
por: Ujiie, Mugen, et al.
Publicado: (2021)

An ethics of HPV vaccination: beyond principlism
por: Stoeklé, Henri-Corto, et al.
Publicado: (2022)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Individual, systemic and state factors associated with provider recommendation of HPV vaccination: Findings from NIS-Teen, 2020
por: Osaghae, Ikponmwosa, et al.
Publicado: (2023)

Medical students’ knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer
por: Du, Eric Y., et al.
Publicado: (2022)

Multilevel perspectives on school-based opportunities to improve HPV vaccination among medically underserved adolescents: Beyond school entry mandates
por: Shin, Michelle B., et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil
por: Fonseca, Allex Jardim, et al.
Publicado: (2014)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ic45hgs8h2if6cebtmgt76mrrq